Biomarkers /
SNCAIP
Overview
Synuclein alpha interacting protein (SNCAIP) is a gene that encodes a protein that functions in neuronal tissue and may play a role in neurodegeneration. Missense mutations, synonymous mutations, and nonsense mutations are observed in cancers such as skin cancer, parathyroid cancer, and stomach cancer.
SNCAIP is altered in 3.11% of all cancers with cutaneous melanoma, melanoma, colon adenocarcinoma, breast invasive ductal carcinoma, and desmoplastic melanoma having the greatest prevalence of alterations [3].
The most common alterations in SNCAIP are SNCAIP Mutation (3.06%), SNCAIP K230E (0.15%), SNCAIP P734S (0.09%), SNCAIP D419N (0.10%), and SNCAIP E627K (0.10%) [3].
Clinical Trials
Significance of SNCAIP in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.